Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption.
Berberine
Depression
NLRP3 inflammasome
Neuroinflammation
Synaptic plasticity
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
received:
02
07
2022
accepted:
21
02
2023
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
Neuroinflammation has been suggested that affects the processing of depression. There is renewed interest in berberine owing to its anti-inflammatory effects. Herein, we investigated whether berberine attenuate depressive-like behaviors via inhibiting NLRP3 inflammasome activation in mice model of depression. Adult male C57BL/6N mice were administrated corticosterone (CORT, 20 mg/kg/day) for 35 days. Two doses (100 mg/kg/day and 200 mg/kg/day) of berberine were orally administrated from day 7 until day 35. Behavioral tests were performed to measure the depression-like behaviors alterations. Differentially expressed gene analysis was performed for RNA-sequencing data in the prefrontal cortex. NLRP3 inflammasome was measured by quantitative reverse transcription polymerase chain reaction, western blotting, and immunofluorescence labeling. The neuroplasticity and synaptic function were measured by immunofluorescence labeling, Golgi-Cox staining, transmission electron microscope, and whole-cell patch-clamp recordings. The results of behavioral tests demonstrated that berberine attenuated the depression-like behaviors induced by CORT. RNA-sequencing identified that NLRP3 was markedly upregulated after long-term CORT exposure. Berberine reversed the concentrations of peripheral and brain cytokines, NLRP3 inflammasome elicited by CORT in the prefrontal cortex and hippocampus were decreased by berberine. In addition, the lower frequency of neuronal excitation as well as the dendritic spine reduction were reversed by berberine treatment. Together, berberine increases hippocampal adult neurogenesis and synaptic plasticity induced by CORT. The anti-depressants effects of berberine were accompanied by reduced the neuroinflammatory response via inhibiting the activation of NLRP3 inflammasome and rescued the neuronal deterioration via suppression of impairments in synaptic plasticity and neurogenesis.
Identifiants
pubmed: 36859349
doi: 10.1186/s12974-023-02744-7
pii: 10.1186/s12974-023-02744-7
pmc: PMC9976521
doi:
Substances chimiques
Berberine
0I8Y3P32UF
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nlrp3 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : National Natural Science Foundation of China
ID : 31900730
Organisme : Shanghai Science and Technology Committee
ID : 20XD1423100
Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
J Neuroinflammation. 2020 Aug 22;17(1):246
pubmed: 32828124
Nat Commun. 2018 Feb 2;9(1):477
pubmed: 29396460
J Neuroinflammation. 2022 Jun 6;19(1):132
pubmed: 35668399
Cell Biosci. 2020 Mar 5;10:28
pubmed: 32166013
Phytother Res. 2023 Jan;37(1):342-357
pubmed: 36089660
J Neuroinflammation. 2017 Jul 21;14(1):139
pubmed: 28732502
Nat Rev Drug Discov. 2018 Sep;17(9):688
pubmed: 30116046
Curr Neuropharmacol. 2018 Jan 30;16(2):176-209
pubmed: 28847294
Trends Immunol. 2015 Oct;36(10):605-613
pubmed: 26431938
J Alzheimers Dis. 2015;43(1):291-302
pubmed: 25079795
J Neurosci. 2011 Nov 9;31(45):16241-50
pubmed: 22072675
Annu Rev Med. 2015;66:509-23
pubmed: 25341010
J Cell Mol Med. 2019 Jan;23(1):21-28
pubmed: 30450823
Front Immunol. 2020 Mar 05;11:388
pubmed: 32194572
Brain Res. 2021 Feb 1;1752:147220
pubmed: 33358726
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Psychopharmacology (Berl). 2019 Jul;236(7):2173-2185
pubmed: 30847567
J Neuroinflammation. 2020 Apr 7;17(1):109
pubmed: 32264970
N Engl J Med. 2008 Jan 3;358(1):55-68
pubmed: 18172175
Lancet Psychiatry. 2022 Feb;9(2):137-150
pubmed: 35026139
Biol Psychiatry. 2009 May 1;65(9):732-41
pubmed: 19150053
Brain Behav Immun. 2017 Aug;64:367-383
pubmed: 28263786
CNS Neurosci Ther. 2014 Mar;20(3):294-5
pubmed: 24479787
Trends Pharmacol Sci. 2008 Aug;29(8):402-12
pubmed: 18617277
Nat Neurosci. 2005 May;8(5):664-72
pubmed: 15834420
Front Neurol. 2018 Mar 20;9:167
pubmed: 29615964
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Neural Plast. 2017;2017:4605971
pubmed: 28491480
Mol Neurobiol. 2018 Dec;55(12):9334-9348
pubmed: 29675572
Curr Neuropharmacol. 2019;17(6):563-579
pubmed: 29676231
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 2;90:104-116
pubmed: 30472146
Science. 2012 Oct 5;338(6103):68-72
pubmed: 23042884
J Neurosci. 2015 Jun 3;35(22):8384-93
pubmed: 26041908
JCI Insight. 2021 Dec 8;6(23):
pubmed: 34877938
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):21-32
pubmed: 31658959
J Neuroinflammation. 2017 May 10;14(1):102
pubmed: 28486969
J Psychiatry Neurosci. 2019 Mar 01;44(3):147-150
pubmed: 31038297
Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559
pubmed: 28479211
Eur J Neurosci. 2021 Jan;53(1):151-171
pubmed: 32150310
Brain Behav Immun. 2007 Mar;21(3):259-72
pubmed: 17194565
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Brain Behav Immun. 2014 Feb;36:111-7
pubmed: 24513871
Front Psychiatry. 2022 Feb 28;13:814828
pubmed: 35295780
Brain Res Bull. 2017 Sep;134:220-227
pubmed: 28842306